Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

NCT02109315 · Withdrawn

Last updated 2026-05-28

This clinical trial tests whether vitamin C and the medication liraglutide can help reduce oxidative stress, inflammation, and blood vessel damage in adults with type 1 diabetes.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Who can join Ages 18–65 · all sexes

Timeline Started 2014-05 · est. completion 2015-05

Where 1 site · Spain

What this study is testing ClinicalTrials.gov NCT02109315 ↗

Description as written by the study sponsor.

To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

Treatments tested

Vitamine C Drug

C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
Liraglutide 6 mg Drug

Liraglutide endovenous de 0.6 mg. one time a day

Main thing measured	Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.
Sponsor	Anna Cruceta
Conditions studied	Type 1 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02109315 ↗